Sign in

Lost your password?
(close)

GLOBAL

Novavax / From No-Hoper to COVID-19 Vaccine Saviour?

From almost being de-listed by the NASDAQ stock index in 2018 due to poor financial performance, US vaccine firm Novavax has completed a remarkable turnaround. Now the holder of one…

Global / Top 5 CDMOs

As the global pharmaceutical industry continues to grow, so have opportunities for service providers. Over the last…

Vaccines / IFPMA's Thomas Cueni on why "#TeamVaccines is all of us"

Thomas Cueni of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) highlights…

The COVID-19 Vaccine Rush / Nationalism, Access & IP Issues

The global rush to secure access to COVID-19 vaccines has led to accusations that richer countries are hoarding…

In Conversation

The bright future of mRNA technology – InConversation Podcast #Episode1: w/Thomas D. Madden, Founder, Acuitas Therapeutics

Dr Thomas D. Madden, CEO and founder of Acuitas Therapeutics, shares the story behind their involvement in Pfizer and BioNTech’s COVID-19 vaccine, the numerous applications of the company’s proprietary lipid nanoparticle (LNP) delivery technology, as well as the growth strategy of the Canadian company. pharmaboardroom · The bright future of mRNA technology w/Acuitas Therapeutics

Novavax: From No-Hoper to COVID-19 Vaccine Saviour?

Novavax: From No-Hoper to COVID-19 Vaccine Saviour?

Vaccines / Manufacturing & Supply Chain Complexity

Pharma industry insiders view vaccines as one of the most challenging products to manufacture, fundamentally due to…

Cell & Gene Therapy / Collaborative Spirit

One of the more intriguing aspects about the new wave of cell and gene therapies (CGT) coming onstream is that they…

Novavax / From No-Hoper to COVID-19 Vaccine Saviour?

From almost being de-listed by the NASDAQ stock index in 2018 due to poor financial performance, US vaccine firm…

Cell & Gene Therapy / Reconsidering Manufacturing

Advances in cell and gene therapies (CGT) are credited with thoroughly transforming medicinal science and creating…

Cell & Gene Therapy / Curing the Incurable: A New Age for Pharmacovigilance

Bayer’s Michael Levy casts his eye over the implications of the advent of cell and gene therapies on…

Cell & Gene Therapy / Funding the Boom

The ascent of cell and gene therapies (CGT) is commonly regarded as one of the momentous turning points in the…

We use cookies to ensure that we give you the best experience on our site. For more info click here